120 related articles for article (PubMed ID: 38530319)
1. Serum fibroblast growth factor 19 level correlates inversely with clinical and endoscopic activity of inflammatory bowel disease.
Łukawska A; Mulak A
Adv Clin Exp Med; 2024 Mar; ():. PubMed ID: 38530319
[TBL] [Abstract][Full Text] [Related]
2. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
Battat R; Duijvestein M; Vande Casteele N; Singh S; Dulai PS; Valasek MA; Mimms L; McFarland J; Hester KD; Renshaw M; Jain A; Sandborn WJ; Boland BS
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2722-2730.e4. PubMed ID: 30448597
[TBL] [Abstract][Full Text] [Related]
3. An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis.
Panek-Jeziorna M; Mulak A
Gastroenterol Res Pract; 2020; 2020():2389312. PubMed ID: 32565779
[TBL] [Abstract][Full Text] [Related]
4. Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.
Nolan JD; Johnston IM; Pattni SS; Dew T; Orchard TR; Walters JR
J Crohns Colitis; 2015 Feb; 9(2):125-31. PubMed ID: 25518063
[TBL] [Abstract][Full Text] [Related]
5. [Inflammatory bowel disease in children--an analysis of the clinical symptoms and selected biochemical parameters].
Landowski P; Liberek A; Szlagatys-Sidorkiewicz A; Radys W; Brodzicki J; Szarszewski A; Marek A; Łuczak G; Kamińska B
Med Wieku Rozwoj; 2007; 11(4):401-7. PubMed ID: 18605192
[TBL] [Abstract][Full Text] [Related]
6. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
7. Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of serum miR-486 and miR-25 in ulcerative colitis and Crohn's disease: Correlations with disease activity, extent, and location.
Abdelazim SA; Shaker OG; Ali O; El-Tawil M; Senousy MA
Pathol Res Pract; 2023 Dec; 252():154910. PubMed ID: 37939427
[TBL] [Abstract][Full Text] [Related]
9. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
[TBL] [Abstract][Full Text] [Related]
10. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
11. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.
Lenicek M; Duricova D; Komarek V; Gabrysova B; Lukas M; Smerhovsky Z; Vitek L
Inflamm Bowel Dis; 2011 Jun; 17(6):1322-7. PubMed ID: 21058331
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
13. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASE.
Lacombe LAC; Matiollo C; Rosa JSD; Felisberto M; Dalmarco EM; Schiavon LL
Arq Gastroenterol; 2022; 59(2):238-243. PubMed ID: 35830035
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
[TBL] [Abstract][Full Text] [Related]
15. Soluble ST2: a new and promising activity marker in ulcerative colitis.
Díaz-Jiménez D; Núñez LE; Beltrán CJ; Candia E; Suazo C; Alvarez-Lobos M; González MJ; Hermoso MA; Quera R
World J Gastroenterol; 2011 May; 17(17):2181-90. PubMed ID: 21633527
[TBL] [Abstract][Full Text] [Related]
16. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
17. Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings.
Gothe F; Beigel F; Rust C; Hajji M; Koletzko S; Freudenberg F
J Crohns Colitis; 2014 Sep; 8(9):1072-8. PubMed ID: 24666974
[TBL] [Abstract][Full Text] [Related]
18. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.
Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP
World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
20. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
Wen N; Zhao N; Xu H; Zhao Y; Ma J
Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
